Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

V. G. Atkinson; A. Hauschild; M. Santinami; M. Mandala; V. Chiarion Sileni; J. Larkin; M. S. Nyakas; C. Dutriaux; A. Haydon; L. Mortier; C. Robert; J. Schachter; D. Schadendorf; X. Feng; E. de Jong; B. Mookerjee; R. Kefford; R. Dummer; J. M. Kirkwood; G. V. Long

doi:10.1093/annonc/mdy289.007

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

V. G. Atkinson, A. Hauschild, M. Santinami, M. Mandala, V. Chiarion Sileni, J. Larkin, M. S. Nyakas, C. Dutriaux, A. Haydon, L. Mortier, C. Robert, J. Schachter, D. Schadendorf, X. Feng, E. de Jong, B. Mookerjee, R. Kefford, R. Dummer, J. M. Kirkwood, G. V. Long

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	1251P
Pages (from-to)	viii446
Number of pages	1
Journal	Annals of Oncology
Volume	29
Issue number	Supplement 8
DOIs	https://doi.org/10.1093/annonc/mdy289.007
Publication status	Published - 1 Oct 2018
Event	43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Access to Document

10.1093/annonc/mdy289.007

Cite this

Atkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M., & Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. Annals of Oncology, 29(Supplement 8), viii446. Article 1251P. https://doi.org/10.1093/annonc/mdy289.007

@article{91b99b6c5afa4c289dd098c5950d79ee,

title = "Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial",

author = "Atkinson, {V. G.} and A. Hauschild and M. Santinami and M. Mandala and {Chiarion Sileni}, V. and J. Larkin and Nyakas, {M. S.} and C. Dutriaux and A. Haydon and L. Mortier and C. Robert and J. Schachter and D. Schadendorf and X. Feng and {de Jong}, E. and B. Mookerjee and R. Kefford and R. Dummer and Kirkwood, {J. M.} and Long, {G. V.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.007",

language = "English",

volume = "29",

pages = "viii446",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Supplement 8",

note = "43rd European Society for Medical Oncology Congress (ESMO 2018) ; Conference date: 19-10-2018 Through 23-10-2018",

}

Atkinson, VG, Hauschild, A, Santinami, M, Mandala, M, Chiarion Sileni, V, Larkin, J, Nyakas, MS, Dutriaux, C, Haydon, A, Mortier, L, Robert, C, Schachter, J, Schadendorf, D, Feng, X, de Jong, E, Mookerjee, B, Kefford, R, Dummer, R, Kirkwood, JM & Long, GV 2018, 'Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial', Annals of Oncology, vol. 29, no. Supplement 8, 1251P, pp. viii446. https://doi.org/10.1093/annonc/mdy289.007

TY - JOUR

T1 - Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

AU - Atkinson, V. G.

AU - Hauschild, A.

AU - Santinami, M.

AU - Mandala, M.

AU - Chiarion Sileni, V.

AU - Larkin, J.

AU - Nyakas, M. S.

AU - Dutriaux, C.

AU - Haydon, A.

AU - Mortier, L.

AU - Robert, C.

AU - Schachter, J.

AU - Schadendorf, D.

AU - Feng, X.

AU - de Jong, E.

AU - Mookerjee, B.

AU - Kefford, R.

AU - Dummer, R.

AU - Kirkwood, J. M.

AU - Long, G. V.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy289.007

DO - 10.1093/annonc/mdy289.007

M3 - Meeting abstract

C2 - 32137134

SN - 0923-7534

VL - 29

SP - viii446

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 8

M1 - 1251P

T2 - 43rd European Society for Medical Oncology Congress (ESMO 2018)

Y2 - 19 October 2018 through 23 October 2018

ER -